Ibiglustat (succinate)

Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].

Product Specifications

CAS Number

[1629063-80-4]

Product Name Alternative

Venglustat (succinate) ; SAR402671 (succinate) ; GZ402671 (succinate)

UNSPSC

12352005

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ibiglustat-succinate.html

Purity

99.71

Solubility

DMSO : ≥ 250 mg/mL

Smiles

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C.OC(CCC(O)=O)=O

Molecular Formula

C24H30FN3O6S

Molecular Weight

507.57

References & Citations

[1]Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11 (1) :20945. Published 2021 Oct 22. |[2]Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10 (1) :86-98. |[3]Iva Stojkovska, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease. Cell Tissue Res. 2017.|[4]Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014;37 (6) :1013-1022.